Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$4.05 USD
-1.96 (-32.61%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $4.04 -0.01 (-0.25%) 7:46 PM ET
5-Strong Sell of 5 5
C Value B Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Ironwood Pharmaceuticals, Inc. [IRWD]
Reports for Purchase
Showing records 981 - 1000 ( 1026 total )
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Q4:12 EPS, All Eyes on Linzess Launch, We Believe Risks Outweigh Rewards, Reiterate UNDERPERFORM; PT to $11
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
$175M Debt Deal Solves Near-Term Cash Crunch at a Cost, We Still Project Significant Cash Needs, Reiterate UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Top-line Plecanatide Data Shows Lower Clinical Benefit Rate vs. Linaclotide and Misses Some Secondary Endpoints - Reiterate UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
AZ China Deal Nets $25 Million - NEXIUM Co-promote Doesn''t Off-Set LINZESS Detail Costs - Cash Needs Remain - REITERATE UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Q3:12 Financial Update -- 3 Quarters of Cash - Reiterate UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of October 14
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pricing Announcement Next, Launch Risks Ahead -- Reiterate UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G